Press Releases April 22, 2026 05:01 PM

Willis Lease Finance Corporation Announces Timing of First Quarter 2026 Financial Results and Conference Call

Willis Lease Finance Corporation Sets Date for Q1 2026 Earnings Release and Conference Call

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
WLFC

Willis Lease Finance Corporation announced it will release its financial results for the first quarter of 2026 on May 5, 2026, before market open, followed by a management-led conference call. The company is a leading lessor of commercial aircraft engines and provider of aviation services.

Willis Lease Finance Corporation Announces Timing of First Quarter 2026 Financial Results and Conference Call
WLFC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Scheduled earnings release for Q1 2026 on May 5, 2026, with a conference call for investors.
  • WLFC specializes in leasing commercial aircraft engines and offers aviation maintenance and support services.
  • The announcement provides details for participation in the earnings conference call and digital replay access.

COCONUT CREEK, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (NASDAQ: WLFC) (the “Company”), the leading lessor of commercial aircraft engines and global provider of aviation services, today announced it will release its financial results for the first quarter of 2026 before the market opens on May 5, 2026. The Company will host a conference call led by the executive management team that day at 10:00 a.m. Eastern Time.

To participate in the conference call, please use the following dial-in numbers:

U.S. and Canada: +1 (800) 330-6730
International: +1 (786) 297-8585
Conference ID: 3012326
Participant Passcode: 989617

The conference call may also be accessed by registering via the following link:
https://event.webcasts.com/starthere.jsp?ei=1759374&tp_key=c0ab3b632b.

A digital replay will be available two hours after the completion of the conference call. To access the replay, please visit our website at www.wlfc.global under the Investor Center section for details.

About Willis Lease Finance Corporation

Willis Lease Finance Corporation (WLFC) leases large and regional spare commercial aircraft engines and aircraft to airlines, aircraft engine manufacturers and maintenance, repair, and overhaul providers worldwide. These leasing activities are integrated with engine and aircraft trading, engine lease pools and asset management services, as well as various end-of-life solutions for engines and aviation materials provided through Willis Aeronautical Services, Inc. Additionally, through Willis Engine Repair Center®, Jet Centre by Willis and Willis Aviation Services Limited, the company’s service offerings include Part 145 engine maintenance, aircraft line and base maintenance, aircraft disassembly, parking and storage, airport FBO and ground and cargo handling services.

CONTACT:Scott B. Flaherty Executive Vice President &
Chief Financial Officer [email protected] 561.413.0112

Risks

  • Financial performance may be impacted by airline industry demand fluctuations affecting leasing and maintenance services.
  • Global economic or geopolitical developments could influence air travel and aircraft leasing markets.
  • Operational risks related to aviation maintenance and service delivery could affect the company's financial results.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026